Prokarium Ltd. has obtained FDA clearance of its IND application for ZH-9 for patients with non-muscle invasive bladder cancer.

Bayer AG and the Broad Institute of MIT and Harvard have extended their research collaboration by an additional 5 years.

Among the avalanche of abstracts for the upcoming American Society of Hematology (ASH) annual conference released early on Nov. 2 were data from Arcellx Inc.’s phase I study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma. The results caught investors’ attention as the company’s stock (NASDAQ:ACLX) jumped 18.5% upward to close at $40.77 per share.

Quibim SL and Royal Philips NV have teamed up to utilize their artificial intelligence (AI)-enabled solutions to help clinicians deliver faster diagnosis and treatment of patients with prostate cancer. The partnership will see Philips AI-based magnetic resonance (MR) imaging technology integrated into Quibim’s AI based QP-Prostate software, to automate real-time prostate gland segmentation in MR images, and generate meaningful quantitative insights, as well as standardize MRI prostate exam reporting.

Blueprint Medicines Corp. has synthesized EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer, particularly non-small-cell lung cancer.

Shenzhen Maxinovel Pharmaceuticals Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase binding moiety covalently bonded to a Wee1-like protein kinase (Wee1)-targeting moiety through a linker.

Engine Biosciences Pte. Ltd. has completed a $27 million series A extension to support the progression of the company’s biomarker and target discoveries toward the clinic through internal development, collaborations and partnerships.

Researchers from Taisho Pharmaceutical Co. Ltd. have discovered new heparanase-1 (HPSE1) inhibitors for the treatment of cancer and proteinuric kidney diseases.